BioPharma Resources

Drug Trial Radar · NCT06497504

Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection on Antiretroviral Treatment

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 153 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

153

Actual

Start

Sep 17, 2024

Primary completion

Apr 22, 2027

Study completion Apr 22, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jul 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.

Conditions

  • Hepatitis B

Interventions

  • BepirovirsenDrug

    Bepirovirsen will be administered.

  • PlaceboDrug

    Placebo will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants achieving hepatitis B virus (HBV) virologic response at 36 weeks after scheduled end of study treatment in absence of rescue medicationTime frame: At study week 60

Locations

51 sites in 10 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    West Palm Beach, Florida

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Minneapolis, Minnesota

  • GSK Investigational Site

    Hillsborough, New Jersey

  • GSK Investigational Site

    Almagro, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    La Plata, Argentina

  • GSK Investigational Site

    Rosario, Argentina

  • GSK Investigational Site

    Aracaju, Brazil

  • GSK Investigational Site

    Campinas, Brazil

  • GSK Investigational Site

    Curitiba, Brazil

  • GSK Investigational Site

    Manaus, Brazil

  • GSK Investigational Site

    Salvador, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Ottawa, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Québec, Quebec, Canada

  • GSK Investigational Site

    Marseille, France

  • GSK Investigational Site

    Melun, France

  • GSK Investigational Site

    Montpellier, France

  • GSK Investigational Site

    Nantes, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Genova, Italy

  • GSK Investigational Site

    Milan, Italy

  • GSK Investigational Site

    Milan, Italy

  • GSK Investigational Site

    Naples, Italy

  • GSK Investigational Site

    Roma, Italy

  • GSK Investigational Site

    Sassari, Italy

  • GSK Investigational Site

    Ekurhuleni, South Africa

  • GSK Investigational Site

    Johannesburg, South Africa

  • GSK Investigational Site

    Durban, KwaZulu-Natal, South Africa

  • GSK Investigational Site

    Barcelona, Spain

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.